{"product_id":"pocket-guide-to-gastrointestinai-drugs-isbn-9781118481578","title":"Pocket Guide to GastrointestinaI Drugs","description":"\u003cb\u003eLearn all you need to know about gastrointestinal drugs and their clinical use with this one-stop, rapid reference pocket guide.\u003c\/b\u003e \u003cp\u003eBrought to you by many of the world's leading GI drug experts, \u003ci\u003ePocket Guide to Gastrointestinal Drugs\u003c\/i\u003e provides comprehensive guidance to the pharmacological properties of drugs used to treat gastrointestinal conditions, including mechanisms of action, appropriate administration, and potential adverse effects associated with their use.\u003c\/p\u003e \u003cp\u003eOrganized by class of drug and ranging from PPIs to immunosupressants, each chapter first examines the specific agents within that class and then their appropriate and judicious use across a range of specific GI disorders.\u003c\/p\u003e \u003cp\u003eKey features include:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIntroduction of drug class\u003c\/li\u003e \u003cli\u003eBasic pharmacology, including mechanism of action, bioavailability, metabolism, interactions, adverse effects, toxicity, and special considerations\u003c\/li\u003e \u003cli\u003eDosing information for each GI condition and on- and off-label use\u003c\/li\u003e \u003cli\u003eConsistent use of both generic and trade names throughout\u003c\/li\u003e \u003cli\u003eSpecific reference to drug use in pediatric patients and during pregnancy\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ePerfect for quick consultation on the wards and in the office, \u003ci\u003ePocket Guide to Gastrointestinal Drugs\u003c\/i\u003e is the ideal tool for all those managing patients with GI conditions, including gastroenterologists, GI trainees, emergency physicians, GI specialist nurses, primary care physicians and residents, intensivists and pharmacists.\u003c\/p\u003e  \u003cp\u003e\u003ci\u003eList of contributors, xi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003ePreface, xvi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I: UPPER GI TRACT\u003c\/b\u003e\u003cbr\u003e \u003cbr\u003e \u003cb\u003e1 Prokinetic agents and antiemetics, 3\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHemangi Kale and Ronnie Fass\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eProkinetics, 3\u003c\/p\u003e \u003cp\u003eAntiemetic agents, 7\u003c\/p\u003e \u003cp\u003eRecommended reading, 14\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Proton pump inhibitors, 15\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eWanda P. Blanton and M. Michael Wolfe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 15\u003c\/p\u003e \u003cp\u003eMechanism of action, pharmacodynamics, kinetics, 15\u003c\/p\u003e \u003cp\u003eClinical use and dosing, 18\u003c\/p\u003e \u003cp\u003eAdverse effects\/safety, 27\u003c\/p\u003e \u003cp\u003eRecommended reading, 28\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Histamine H2-receptor antagonists, 31\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKentaro Sugano\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 31\u003c\/p\u003e \u003cp\u003eMechanism of action, 31\u003c\/p\u003e \u003cp\u003ePharmacology, 33\u003c\/p\u003e \u003cp\u003eClinical effectiveness, 40\u003c\/p\u003e \u003cp\u003eAdverse events, 41\u003c\/p\u003e \u003cp\u003eRecommended reading, 42\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Prostaglandins and other mucosal protecting agents, 44\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCarlos Sostres and Angel Lanas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction of drug class, 44\u003c\/p\u003e \u003cp\u003ePhysicochemical properties, 45\u003c\/p\u003e \u003cp\u003eFormulations and recommended dosages, 46\u003c\/p\u003e \u003cp\u003eMechanism of action, 47\u003c\/p\u003e \u003cp\u003eDrug interactions, 48\u003c\/p\u003e \u003cp\u003ePharmacokinetics, 49\u003c\/p\u003e \u003cp\u003eClinical effectiveness, 49\u003c\/p\u003e \u003cp\u003eToxicity, 51\u003c\/p\u003e \u003cp\u003ePregnancy classes, 52\u003c\/p\u003e \u003cp\u003eOther mucosal protecting agents, 52\u003c\/p\u003e \u003cp\u003eRecommended reading, 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II: SMALL AND LARGE INTESTINE\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 5-HT modulators and other antidiarrheal agents and cathartics, 59\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlbena Halpert and Douglas Drossman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 59\u003c\/p\u003e \u003cp\u003e5-HT modulators used in the management of GI disorders, 59\u003c\/p\u003e \u003cp\u003e5-HT agents approved in the US for specific GI indications, 60\u003c\/p\u003e \u003cp\u003eMedications used for the treatment of chronic constipation, 71\u003c\/p\u003e \u003cp\u003eMedications used for the treatment of narcotic-induced constipation, 76\u003c\/p\u003e \u003cp\u003eAntidiarrheal agents, 76\u003c\/p\u003e \u003cp\u003eConclusion, 80\u003c\/p\u003e \u003cp\u003eRecommended reading, 80\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 5-aminosalicylates, 82\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eHannah L. Miller and Francis A. Farraye\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 82\u003c\/p\u003e \u003cp\u003ePreparations, 82\u003c\/p\u003e \u003cp\u003eClinical use and efficacy, 84\u003c\/p\u003e \u003cp\u003ePharmacology: preparations and dosing, 87\u003c\/p\u003e \u003cp\u003eMechanism of action, 89\u003c\/p\u003e \u003cp\u003eBioavailability and metabolism, 89\u003c\/p\u003e \u003cp\u003eAdverse effects and toxicity, 91\u003c\/p\u003e \u003cp\u003ePregnancy, 93\u003c\/p\u003e \u003cp\u003eDrug interactions (package inserts), 94\u003c\/p\u003e \u003cp\u003ePrecautions and contraindications, 94\u003c\/p\u003e \u003cp\u003eSpecial considerations: effectiveness in colorectal cancer prevention, 96\u003c\/p\u003e \u003cp\u003eConclusion, 97\u003c\/p\u003e \u003cp\u003eRecommended reading, 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Immunosuppressive agents, 100\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eLev Lichtenstein and Gerald M. Fraser\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 100\u003c\/p\u003e \u003cp\u003eThiopurines, 100\u003c\/p\u003e \u003cp\u003eLow-dose methotrexate (MTX), 106\u003c\/p\u003e \u003cp\u003eCalcineurin inhibitors, 111\u003c\/p\u003e \u003cp\u003eRecommended reading, 114\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Biological agents, 117\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eGert Van Assche\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eBiological agents approved to treat IBD, 117\u003c\/p\u003e \u003cp\u003eOptimal treatment strategies with anti TNF therapies in IBD, 119\u003c\/p\u003e \u003cp\u003eSafety of biological agents in IBD, 120\u003c\/p\u003e \u003cp\u003eEmerging biologicals, 121\u003c\/p\u003e \u003cp\u003eRecommended reading, 121\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III: LIVER AND PANCREAS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Interferons, 125\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eRobert C. Lowe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 125\u003c\/p\u003e \u003cp\u003eMechanism of action, 125\u003c\/p\u003e \u003cp\u003ePharmacology, 126\u003c\/p\u003e \u003cp\u003eClinical effectiveness, 127\u003c\/p\u003e \u003cp\u003eToxicity, 128\u003c\/p\u003e \u003cp\u003eInterferon types with generic and brand names, 129\u003c\/p\u003e \u003cp\u003ePregnancy classes, 130\u003c\/p\u003e \u003cp\u003eInitial interferon dosing regimens for chronic hepatitis C, 130\u003c\/p\u003e \u003cp\u003eRecommended reading, 131\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Nucleoside analogs, 133\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eUri Avissar and David P. Nunes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 133\u003c\/p\u003e \u003cp\u003eMechanism of action, 135\u003c\/p\u003e \u003cp\u003ePharmacology, 137\u003c\/p\u003e \u003cp\u003eClinical effectiveness, 139\u003c\/p\u003e \u003cp\u003eNucleoside analogs, 141\u003c\/p\u003e \u003cp\u003eNucleotide analogs, 146\u003c\/p\u003e \u003cp\u003eSummary, 147\u003c\/p\u003e \u003cp\u003eRecommended reading, 148\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Ursodeoxycholic acid, chelating agents, and zinc in the treatment of metabolic liver diseases, 150\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAndrew K. Burroughs and James S. Dooley\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eUrsodeoxycholic acid, 150\u003c\/p\u003e \u003cp\u003eTreatment of copper overload, 155\u003c\/p\u003e \u003cp\u003eRecommended reading, 162\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Agents for the treatment of portal hypertension, 165\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eKaren L. Krok and Andrés Cárdenas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 165\u003c\/p\u003e \u003cp\u003eNonselective beta-blockers (NSBB), 166\u003c\/p\u003e \u003cp\u003eNitrates, 169\u003c\/p\u003e \u003cp\u003eVasopressin analogs, 169\u003c\/p\u003e \u003cp\u003eSomatostatin analog, 170\u003c\/p\u003e \u003cp\u003eMidodrine, 171\u003c\/p\u003e \u003cp\u003eAlbumin, 172\u003c\/p\u003e \u003cp\u003eLoop diuretics, 172\u003c\/p\u003e \u003cp\u003eAldosterone antagonist, 174\u003c\/p\u003e \u003cp\u003eAquaretics, 174\u003c\/p\u003e \u003cp\u003eDisaccharides, 175\u003c\/p\u003e \u003cp\u003eAntibiotics, 176\u003c\/p\u003e \u003cp\u003eRecommended reading, 177\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Pancreatic enzymes, 179\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSteven J. Czinn and Samra S. Blanchard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 179\u003c\/p\u003e \u003cp\u003eMechanism of action, 180\u003c\/p\u003e \u003cp\u003eDosing and schedule of administration, 180\u003c\/p\u003e \u003cp\u003eMonitoring therapy, 183\u003c\/p\u003e \u003cp\u003eAdverse effects, 183\u003c\/p\u003e \u003cp\u003eRecommended reading, 184\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV: ANTIMICROBIALS AND VACCINES\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Antibiotics for the therapy of gastrointestinal diseases, 187\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eMelissa Osborn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 187\u003c\/p\u003e \u003cp\u003ePharmacologic properties, 187\u003c\/p\u003e \u003cp\u003eClinical uses, 195\u003c\/p\u003e \u003cp\u003eRecommended reading, 202\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Antimicrobials for parasitic diseases, 204\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJoachim Richter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5-Nitroimidazoles, 204\u003c\/p\u003e \u003cp\u003eBenzimidazoles, 206\u003c\/p\u003e \u003cp\u003eIvermectin, 211\u003c\/p\u003e \u003cp\u003ePraziquantel, 212\u003c\/p\u003e \u003cp\u003eTreatment dosages, 214\u003c\/p\u003e \u003cp\u003eRecommended reading, 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Vaccines for viral hepatitides, 219\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eSavio John and Raymond T. Chung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eHepatitis A vaccination, 219\u003c\/p\u003e \u003cp\u003eHepatitis B vaccination, 222\u003c\/p\u003e \u003cp\u003eRecommended reading, 227\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Rotavirus and other enteric vaccinations, 229\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eChristopher J. Moran and Esther J. Israel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eRotavirus vaccination, 229\u003c\/p\u003e \u003cp\u003eTyphoid fever vaccination, 232\u003c\/p\u003e \u003cp\u003eRecommended reading, 233\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART V: NUTRITION AND PROBIOTICS\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Parenteral and enteral nutrition feeding formulas, 237\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eDominic N. Reeds and Beth Taylor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 237\u003c\/p\u003e \u003cp\u003eIndications for nutrition support, 237\u003c\/p\u003e \u003cp\u003eEnergy and macronutrient requirements, 237\u003c\/p\u003e \u003cp\u003eProtein, 238\u003c\/p\u003e \u003cp\u003eCarbohydrate, 239\u003c\/p\u003e \u003cp\u003eLipids, 239\u003c\/p\u003e \u003cp\u003eEnteral liquid feeding formulations, 239\u003c\/p\u003e \u003cp\u003eDisease-specifi c formulas, 244\u003c\/p\u003e \u003cp\u003eSelection of an appropriate enteral formula, 245\u003c\/p\u003e \u003cp\u003eImplementation of enteral nutrition, 245\u003c\/p\u003e \u003cp\u003eParenteral nutrition, 245\u003c\/p\u003e \u003cp\u003eSummary, 247\u003c\/p\u003e \u003cp\u003eRecommended reading, 247\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Probiotics, 249\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eChristina M. Surawicz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction, 249\u003c\/p\u003e \u003cp\u003ePharmacology, 250\u003c\/p\u003e \u003cp\u003eMechanisms of action, 251\u003c\/p\u003e \u003cp\u003eClinical indications, 251\u003c\/p\u003e \u003cp\u003eSafety\/toxicity, 255\u003c\/p\u003e \u003cp\u003eSummary, 255\u003c\/p\u003e \u003cp\u003eRecommended reading, 256\u003c\/p\u003e \u003cp\u003eIndex, 259\u003c\/p\u003e \u003cp\u003e“This can be a useful resource. I can see having a copy in my lab coat pocket.”  \u003ci\u003e (Doody’s\u003c\/i\u003e, 9 January 2015)\u003c\/p\u003e  \u003cb\u003eMichael Wolfe\u003c\/b\u003e, M.D is a former Chair of the FDA's advisory board for gastrointestinal drugs. He has achieved significant recognition for his interest in acid-related disorders, specifically GERD, NSAID-associated gastroduodenal ulcers, gastrinoma and other neuroendocrine tumors. He is on the editorial boards of \u003ci\u003eDigestive Diseases and Sciences\u003c\/i\u003e and \u003ci\u003eRegulatory Peptides\u003c\/i\u003e, and served as a member of the editorial board of \u003ci\u003eThe American Journal of Physiology.\u003c\/i\u003e  He has edited several textbooks, including \u003ci\u003eTherapy of Digestive Disorders\u003c\/i\u003e and \u003ci\u003eHeartburn: Extinguishing the Fire Inside\u003c\/i\u003e. In total, he's authored over 300 articles, chapters, abstracts and reviews.  \u003cp\u003e\u003cb\u003eRobert C. Lowe\u003c\/b\u003e, M.D. is the author of numerous book chapters and articles, and is co-editor of \u003ci\u003eEducational Review Manual in Gastroenterology\u003c\/i\u003e and \u003ci\u003eGI Emergencies: A Quick Reference Guide.\u003c\/i\u003e For the past 4 years, he has served as the chairman of the Medical Advisory Committee of the American Liver Foundation, New England Chapter and he is currently serving as a member of the Education and Training Committee of the American Gastroenterological Association.\u003c\/p\u003e \u003cb\u003eLearn all you need to know about gastrointestinal drugs and their clinical use with this one-stop, rapid reference pocket guide.\u003c\/b\u003e \u003cp\u003eBrought to you by many of the world's leading GI drug experts, \u003ci\u003ePocket Guide to Gastrointestinal Drugs\u003c\/i\u003e provides comprehensive guidance to the pharmacological properties of drugs used to treat gastrointestinal conditions, including mechanisms of action, appropriate administration, and potential adverse effects associated with their use.\u003c\/p\u003e \u003cp\u003eOrganized by class of drug and ranging from PPIs to immunosupressants, each chapter first examines the specific agents within that class and then their appropriate and judicious use across a range of specific GI disorders.\u003c\/p\u003e \u003cp\u003eKey features include:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eIntroduction of drug class\u003c\/li\u003e \u003cli\u003eBasic pharmacology, including mechanism of action, bioavailability, metabolism, interactions, adverse effects, toxicity, and special considerations\u003c\/li\u003e \u003cli\u003eDosing information for each GI condition and on- and off-label use\u003c\/li\u003e \u003cli\u003eConsistent use of both generic and trade names throughout\u003c\/li\u003e \u003cli\u003eSpecific reference to drug use in pediatric patients and during pregnancy\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003ePerfect for quick consultation on the wards and in the office, \u003ci\u003ePocket Guide to Gastrointestinal Drugs\u003c\/i\u003e is the ideal tool for all those managing patients with GI conditions, including gastroenterologists, GI trainees, emergency physicians, GI specialist nurses, primary care physicians and residents, intensivists and pharmacists.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989802467557,"sku":"NP9781118481578","price":64.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118481578.jpg?v=1761785525","url":"https:\/\/k12savings.com\/es\/products\/pocket-guide-to-gastrointestinai-drugs-isbn-9781118481578","provider":"K12savings","version":"1.0","type":"link"}